Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership

Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.

As quoted in the press release:

Through this partnership Denali will have access to Lonza’s extensive expertise and technologies: from cell-line development using the GS Xceed^® Gene Expression System to process development and manufacturing at facilities in Slough (UK) and Hayward, CA (USA). In addition, Lonza’s in-house Drug Product Services in Basel (CH) will focus on ensuring that Denali’s finished product candidates are designed with optimal formulation, stability and delivery system in mind.

Click here to read the full press release.